Also trades as: 1801.HK (HKSE) · $vol 173M
IVBXF OTC
Innovent Biologics, Inc.
1W: +2.8%
1M: -0.3%
3M: +9.6%
YTD: +18.3%
1Y: +4.7%
3Y: +260.6%
5Y: +7.6%
$12.80
+0.29 (+2.33%)
Weekly Expected Move ±14.3%
$9
$11
$13
$15
$16
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Cash Flow Trends
Operating Cash Flow
$1.3B
+770.7% ▲
Capital Expenditures
$1.7B
-23.3% ▼
5Y CAGR: +36.1%
Free Cash Flow
-$418M
+66.1% ▲
Dividends Paid
$0
+0.0% ▲
Buybacks
$0
+0.0% ▲
Net Change in Cash
-$472M
-127.3% ▼
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | -$859M | -$2.7B | -$2.2B | -$1.1B | -$95M |
| Depreciation & Amort. | $86M | $205M | $319M | $385M | $420M |
| Stock-Based Comp. | $402M | $502M | $469M | $574M | $557M |
| Change in Working Capital | -$334M | -$90M | $310M | $403M | $450M |
| Other Non-Cash Items | -$5M | $37M | -$847M | -$70M | -$44M |
| Operating Cash Flow | -$308M | -$2.0B | -$1.9B | $148M | $1.3B |
| — Investing Activities — | |||||
| Capital Expenditures | -$772M | -$1.8B | -$1.4B | -$1.1B | $0 |
| Acquisitions (Net) | $89M | -$630M | $0 | $0 | $0 |
| Investment Purchases | -$11.6B | -$10.3B | -$10.3B | -$9.4B | $0 |
| Investment Sales | $7.2B | $10.1B | $10.0B | $9.2B | $0 |
| Other Investing | -$17M | -$4M | $252M | $291M | -$1.2B |
| Investing Cash Flow | -$5.2B | -$2.7B | -$1.4B | -$999M | -$1.2B |
| — Financing Activities — | |||||
| Net Debt Issuance | $355M | $1.2B | $715M | $418M | -$730M |
| Stock Repurchased | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 |
| Other Financing | -$105M | -$155M | $46M | -$86M | $39M |
| Financing Cash Flow | $4.9B | $5.0B | $2.9B | $2.6B | -$607M |
| Net Change in Cash | -$1.1B | $83M | -$343M | $1.7B | -$472M |
| Cash End of Period | $1.3B | $1.4B | $1.0B | $2.7B | $2.3B |
| Free Cash Flow | -$1.1B | -$3.9B | -$3.3B | -$1.2B | -$418M |